12 January 2017 - PHARMAC is pleased to announce the approval of an amendment to the trauma, spine and CMF implants agreement with Stryker.

This was the subject of a consultation letter dated 9 December 2016.

In summary, the effect of the decision is that:

• A range of orthopaedic joint implants, additional CMF implants, associated products and bone cement will be listed in Section H, Part III, (‘Optional Pharmaceuticals’) of the Pharmaceutical Schedule from 1 February 2017.
  
• DHB hospitals can purchase these items directly from Stryker.
  
• For the DHBs that currently use these products the national agreement will deliver savings to some and small increases to others.
  

Read PHARMAC notification